Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

ASO Author Reflections: Mitigating Survival Disparities in African American Women with Breast Cancer within the US Military Healthcare System-The Impact of Equivalent Care.

Hueman MT, Shriver CD, Ellsworth RE.

Ann Surg Oncol. 2019 Oct 28. doi: 10.1245/s10434-019-08007-1. [Epub ahead of print] No abstract available.

PMID:
31659638
2.

Evaluation of Surgical Disparities Between African American and European American Women Treated for Breast Cancer Within an Equal-Access Military Hospital.

Lovejoy LA, Eaglehouse YL, Hueman MT, Mostoller BJ, Shriver CD, Ellsworth RE.

Ann Surg Oncol. 2019 Nov;26(12):3838-3845. doi: 10.1245/s10434-019-07706-z. Epub 2019 Aug 13.

PMID:
31410609
3.

Creating Prognostic Systems for Well-Differentiated Thyroid Cancer Using Machine Learning.

Yang CQ, Gardiner L, Wang H, Hueman MT, Chen D.

Front Endocrinol (Lausanne). 2019 May 8;10:288. doi: 10.3389/fendo.2019.00288. eCollection 2019.

4.

Creating prognostic systems for cancer patients: A demonstration using breast cancer.

Hueman MT, Wang H, Yang CQ, Sheng L, Henson DE, Schwartz AM, Chen D.

Cancer Med. 2018 Aug;7(8):3611-3621. doi: 10.1002/cam4.1629. Epub 2018 Jul 2.

5.

Comparative Survival Analysis of Invasive Breast Cancer Patients Treated by a U.S. Military Medical Center and Matched Patients From the U.S. General Population.

Ru Y, Liu J, Fantacone-Campbell JL, Zhu K, Kovatich AJ, Hooke JA, Kvecher L, Deyarmin B, Kovatich AW, Cammarata F, Hueman MT, Rui H, Mural RJ, Shriver CD, Hu H.

Mil Med. 2017 Nov;182(11):e1851-e1858. doi: 10.7205/MILMED-D-17-00097.

PMID:
29087852
6.

The anatomy of the TNM for colon cancer.

Henson DE, Hueman MT, Chen D, Patel JA, Wang H, Schwartz AM.

J Gastrointest Oncol. 2017 Feb;8(1):12-19. doi: 10.21037/jgo.2016.11.10.

7.

Nonsteroidal anti-inflammatory drugs may affect cytokine response and benefit healing of combat-related extremity wounds.

Lisboa FA, Bradley MJ, Hueman MT, Schobel SA, Gaucher BJ, Styrmisdottir EL, Potter BK, Forsberg JA, Elster EA.

Surgery. 2017 Apr;161(4):1164-1173. doi: 10.1016/j.surg.2016.10.011. Epub 2016 Dec 3.

8.

An Algorithm for Creating Prognostic Systems for Cancer.

Chen D, Wang H, Sheng L, Hueman MT, Henson DE, Schwartz AM, Patel JA.

J Med Syst. 2016 Jul;40(7):160. doi: 10.1007/s10916-016-0518-1. Epub 2016 May 17.

PMID:
27189622
9.

An algorithm for expanding the TNM staging system.

Chen D, Hueman MT, Henson DE, Schwartz AM.

Future Oncol. 2016;12(8):1015-24. doi: 10.2217/fon.16.5. Epub 2016 Feb 24.

PMID:
26904925
10.

Tumour location within the breast: Does tumour site have prognostic ability?

Rummel S, Hueman MT, Costantino N, Shriver CD, Ellsworth RE.

Ecancermedicalscience. 2015 Jul 13;9:552. doi: 10.3332/ecancer.2015.552. eCollection 2015.

11.
12.

Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.

Gates JD, Clifton GT, Benavides LC, Sears AK, Carmichael MG, Hueman MT, Holmes JP, Jama YH, Mursal M, Zacharia A, Ciano K, Khoo S, Stojadinovic A, Ponniah S, Peoples GE.

Vaccine. 2010 Nov 3;28(47):7476-82. doi: 10.1016/j.vaccine.2010.09.029. Epub 2010 Sep 19.

PMID:
20858449
13.

Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.

Patil R, Clifton GT, Holmes JP, Amin A, Carmichael MG, Gates JD, Benavides LH, Hueman MT, Ponniah S, Peoples GE.

J Am Coll Surg. 2010 Feb;210(2):140-7. doi: 10.1016/j.jamcollsurg.2009.10.022. Epub 2009 Dec 22.

PMID:
20113933
14.

Evolving treatment strategies for gallbladder cancer.

Hueman MT, Vollmer CM Jr, Pawlik TM.

Ann Surg Oncol. 2009 Aug;16(8):2101-15. doi: 10.1245/s10434-009-0538-x. Epub 2009 Jun 3. Review.

PMID:
19495882
15.

The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Benavides LC, Gates JD, Carmichael MG, Patil R, Holmes JP, Hueman MT, Mittendorf EA, Craig D, Stojadinovic A, Ponniah S, Peoples GE.

Clin Cancer Res. 2009 Apr 15;15(8):2895-904. doi: 10.1158/1078-0432.CCR-08-1126. Epub 2009 Apr 7. Erratum in: Clin Cancer Res. 2009 Sep 1;15(17):5601. Patel, Ritesh [corrected to Patil, Ritesh].

16.

Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.

Gates JD, Carmichael MG, Benavides LC, Holmes JP, Hueman MT, Woll MM, Ioannides CG, Robson CH, McLeod DG, Ponniah S, Peoples GE.

J Am Coll Surg. 2009 Feb;208(2):193-201. doi: 10.1016/j.jamcollsurg.2008.10.018.

PMID:
19228530
17.

Sentinel lymph node biopsy in melanoma.

Hueman MT, Lange JR.

Curr Treat Options Oncol. 2008 Dec;9(4-6):243-50. doi: 10.1007/s11864-008-0074-0. Epub 2008 Nov 8.

PMID:
18998214
18.

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Holmes JP, Gates JD, Benavides LC, Hueman MT, Carmichael MG, Patil R, Craig D, Mittendorf EA, Stojadinovic A, Ponniah S, Peoples GE.

Cancer. 2008 Oct 1;113(7):1666-75. doi: 10.1002/cncr.23772.

19.

Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.

Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Murray JL, Amin A, Craig D, von Hofe E, Ponniah S, Peoples GE.

J Clin Oncol. 2008 Jul 10;26(20):3426-33. doi: 10.1200/JCO.2007.15.7842.

PMID:
18612158
20.

Management of gastrointestinal stromal tumors.

Hueman MT, Schulick RD.

Surg Clin North Am. 2008 Jun;88(3):599-614, vii. doi: 10.1016/j.suc.2008.03.001. Review.

PMID:
18514701
21.

Management of retroperitoneal sarcomas.

Hueman MT, Herman JM, Ahuja N.

Surg Clin North Am. 2008 Jun;88(3):583-97, vii. doi: 10.1016/j.suc.2008.03.002. Review.

PMID:
18514700
22.

Management of extremity soft tissue sarcomas.

Hueman MT, Thornton K, Herman JM, Ahuja N.

Surg Clin North Am. 2008 Jun;88(3):539-57, vi. doi: 10.1016/j.suc.2008.04.003. Review.

PMID:
18514697
23.

Soft tissue sarcomas. Preface.

Hueman MT, Ahuja N.

Surg Clin North Am. 2008 Jun;88(3):xiii-xvii. doi: 10.1016/j.suc.2008.04.009. No abstract available.

PMID:
18514693
24.

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Amin A, Benavides LC, Holmes JP, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Storrer CE, Jama YH, Craig D, Stojadinovic A, Ponniah S, Peoples GE.

Cancer Immunol Immunother. 2008 Dec;57(12):1817-25. doi: 10.1007/s00262-008-0509-2. Epub 2008 Apr 8.

PMID:
18392824
25.

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S.

Clin Cancer Res. 2008 Feb 1;14(3):797-803. doi: 10.1158/1078-0432.CCR-07-1448.

26.

Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.

Stojadinovic A, Mittendorf EA, Holmes JP, Amin A, Hueman MT, Ponniah S, Peoples GE.

Ann Surg Oncol. 2007 Dec;14(12):3359-68. Epub 2007 Sep 29.

PMID:
17906897
27.

Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology.

Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE.

Oncol Rep. 2007 Mar;17(3):687-94.

PMID:
17273752
28.

Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine.

Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada ZA, Gurney JM, Shriver CD, Ponniah S, Peoples GE.

Cancer Immunol Immunother. 2007 Feb;56(2):135-46. Epub 2006 Jun 17.

PMID:
16783576
29.

Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.

Hueman MT, Stojadinovic A, Storrer CE, Foley RJ, Gurney JM, Shriver CD, Ponniah S, Peoples GE.

Breast Cancer Res Treat. 2006 Jul;98(1):17-29. Epub 2006 Jun 7.

PMID:
16758122
30.

Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.

Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Kao TC, Shriver CD, Ponniah S, Peoples GE.

Clin Cancer Res. 2006 Jan 15;12(2):478-86.

31.

Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.

Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod DG, Ioannides CG, Ponniah S, Peoples GE.

Clin Cancer Res. 2005 Oct 15;11(20):7470-9.

32.

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.

Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S.

J Clin Oncol. 2005 Oct 20;23(30):7536-45. Epub 2005 Sep 12.

PMID:
16157940
33.

The effect of changing gamma count threshold on sentinel lymph node accuracy.

Hueman MT, Scanlan BJ, White PW, Golarz SR, Peoples GE, Shriver CD, Maniscalco-Theberge ME.

Curr Surg. 2002 May-Jun;59(3):313-7.

PMID:
16093154
34.

Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.

Woll MM, Hueman MT, Ryan GB, Ioannides CG, Henderson CG, Sesterhan IA, Shrivasta S, McLeod DG, Moul JW, Peoples GE.

Int J Oncol. 2004 Dec;25(6):1769-80.

PMID:
15547716
35.

Comparison of benefits on myocardial performance of cellular cardiomyoplasty with skeletal myoblasts and fibroblasts.

Hutcheson KA, Atkins BZ, Hueman MT, Hopkins MB, Glower DD, Taylor DA.

Cell Transplant. 2000 May-Jun;9(3):359-68.

PMID:
10972335
36.

Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium.

Atkins BZ, Hueman MT, Meuchel JM, Cottman MJ, Hutcheson KA, Taylor DA.

J Heart Lung Transplant. 1999 Dec;18(12):1173-80.

PMID:
10612375
37.

Cellular cardiomyoplasty improves diastolic properties of injured heart.

Atkins BZ, Hueman MT, Meuchel J, Hutcheson KA, Glower DD, Taylor DA.

J Surg Res. 1999 Aug;85(2):234-42.

PMID:
10423324

Supplemental Content

Loading ...
Support Center